Stock listing
NASDAQ:MTVA MetaVia Inc. Stock
Home listing (NASDAQ) of MetaVia Inc.
Follow MetaVia Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:MTVA
$1.01 USD -0.05 (-4.7%)
Close on Nov 20, 2026
- Day range
- $0.999 – $1.10 USDNov 20, 2026
- Volume
- 38,724 sharesNov 20, 2026
- Market cap
- $6.81M USDAt the close on Nov 20, 2026 · price × 6.74M shares outstanding
- 52-week range
- $0.966 – $13.42 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $160,402 USDMedian day 58,853 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MTVA · Home | $1.01 USD | -0.05 (-4.7%) | 38,724 | $1.059 | $1.10 | $0.999 | $1.06 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MTVA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.01 | -0.05 | -4.7% | $1.059 | $1.10 | $0.999 | 38,724 | |
| $1.06 | -0.19 | -15.2% | $1.22 | $1.24 | $1.06 | 91,476 | |
| $1.25 | +0.045 | +3.7% | $1.23 | $1.38 | $1.186 | 93,884 | |
| $1.205 | -0.095 | -7.3% | $1.28 | $1.30 | $1.185 | 58,853 | |
| $1.30 | 0.00 | 0.0% | $1.431 | $1.431 | $1.251 | 49,172 | |
| $1.30 | -0.14 | -9.7% | $1.45 | $1.45 | $1.295 | 55,064 | |
| $1.44 | -0.05 | -3.4% | $1.48 | $1.609 | $1.402 | 128,885 | |
| $1.49 | -0.12 | -7.5% | $1.60 | $1.66 | $1.49 | 105,041 | |
| $1.61 | +0.18 | +12.6% | $1.40 | $1.776 | $1.33 | 462,543 | |
| $1.43 | +0.34 | +31.2% | $1.10 | $1.44 | $1.09 | 942,700 | |
| $1.09 | -0.25 | -18.7% | $1.40 | $1.423 | $1.016 | 1,078,700 | |
| $1.34 | +0.08 | +6.3% | $1.26 | $1.45 | $1.26 | 147,600 | |
| $1.26 | +0.09 | +7.7% | $1.17 | $1.26 | $1.17 | 73,200 | |
| $1.17 | +0.05 | +4.5% | $1.19 | $1.219 | $1.15 | 54,100 | |
| $1.12 | -0.07 | -5.9% | $1.20 | $1.29 | $1.12 | 72,500 | |
| $1.19 | +0.05 | +4.4% | $1.15 | $1.25 | $1.12 | 66,500 | |
| $1.14 | -0.01 | -0.9% | $1.17 | $1.19 | $1.11 | 93,200 | |
| $1.15 | -0.065 | -5.3% | $1.27 | $1.27 | $1.15 | 68,400 | |
| $1.215 | -0.165 | -12.0% | $1.41 | $1.41 | $1.215 | 136,100 | |
| $1.38 | -0.01 | -0.7% | $1.39 | $1.50 | $1.36 | 99,600 | |
| $1.39 | +0.05 | +3.7% | $1.35 | $1.395 | $1.35 | 33,100 | |
| $1.34 | +0.05 | +3.9% | $1.29 | $1.37 | $1.29 | 42,200 | |
| $1.29 | +0.06 | +4.9% | $1.26 | $1.32 | $1.20 | 21,000 | |
| $1.23 | -0.03 | -2.4% | $1.29 | $1.32 | $1.225 | 54,300 | |
| $1.26 | -0.11 | -8.0% | $1.38 | $1.43 | $1.26 | 75,700 | |
| $1.37 | +0.01 | +0.7% | $1.35 | $1.44 | $1.325 | 50,100 | |
| $1.36 | -0.07 | -4.9% | $1.40 | $1.435 | $1.35 | 40,500 | |
| $1.43 | -0.02 | -1.4% | $1.52 | $1.52 | $1.415 | 65,400 | |
| $1.45 | +0.04 | +2.8% | $1.43 | $1.589 | $1.41 | 137,000 | |
| $1.41 | +0.07 | +5.2% | $1.35 | $1.44 | $1.35 | 49,600 | |
| $1.34 | -0.12 | -8.2% | $1.47 | $1.48 | $1.33 | 112,000 | |
| $1.46 | -0.02 | -1.4% | $1.47 | $1.52 | $1.46 | 30,800 | |
| $1.48 | -0.06 | -3.9% | $1.52 | $1.54 | $1.45 | 86,100 | |
| $1.54 | 0.00 | 0.0% | $1.55 | $1.587 | $1.54 | 53,100 | |
| $1.54 | 0.00 | 0.0% | $1.56 | $1.65 | $1.51 | 61,400 | |
| $1.54 | -0.03 | -1.9% | $1.59 | $1.605 | $1.52 | 46,600 | |
| $1.57 | -0.09 | -5.4% | $1.64 | $1.66 | $1.55 | 65,100 | |
| $1.66 | -0.01 | -0.6% | $1.64 | $1.67 | $1.61 | 26,100 | |
| $1.67 | +0.01 | +0.6% | $1.65 | $1.70 | $1.62 | 135,000 | |
| $1.66 | +0.03 | +1.8% | $1.68 | $1.68 | $1.61 | 28,700 | |
| $1.63 | 0.00 | 0.0% | $1.662 | $1.662 | $1.61 | 63,600 | |
| $1.63 | -0.05 | -3.0% | $1.65 | $1.665 | $1.61 | 37,600 | |
| $1.68 | +0.01 | +0.6% | $1.69 | $1.69 | $1.64 | 31,300 | |
| $1.67 | -0.06 | -3.5% | $1.65 | $1.701 | $1.64 | 45,300 | |
| $1.73 | +0.14 | +8.8% | $1.55 | $1.73 | $1.55 | 103,800 | |
| $1.59 | +0.05 | +3.2% | $1.551 | $1.59 | $1.52 | 38,900 | |
| $1.54 | -0.04 | -2.5% | $1.57 | $1.59 | $1.52 | 45,700 | |
| $1.58 | -0.04 | -2.5% | $1.67 | $1.67 | $1.56 | 52,600 | |
| $1.62 | -0.04 | -2.4% | $1.64 | $1.87 | $1.60 | 76,600 | |
| $1.66 | -0.09 | -5.1% | $1.75 | $1.795 | $1.65 | 57,000 | |
| $1.75 | +0.01 | +0.6% | $1.75 | $1.83 | $1.74 | 104,900 | |
| $1.74 | +0.04 | +2.4% | $1.70 | $1.85 | $1.52 | 609,300 | |
| $1.70 | -0.05 | -2.9% | $1.76 | $1.81 | $1.70 | 42,800 | |
| $1.75 | -0.09 | -4.9% | $1.82 | $1.85 | $1.70 | 81,100 | |
| $1.84 | +0.02 | +1.1% | $1.803 | $1.93 | $1.78 | 82,900 | |
| $1.82 | +0.10 | +5.8% | $1.70 | $1.84 | $1.699 | 79,600 | |
| $1.72 | 0.00 | 0.0% | $1.69 | $1.73 | $1.65 | 51,400 | |
| $1.72 | +0.02 | +1.2% | $1.70 | $1.74 | $1.68 | 23,300 | |
| $1.70 | +0.04 | +2.4% | $1.69 | $1.732 | $1.67 | 37,700 | |
| $1.66 | -0.02 | -1.2% | $1.69 | $1.73 | $1.65 | 39,700 | |
| $1.68 | +0.04 | +2.4% | $1.56 | $1.69 | $1.56 | 48,600 | |
| $1.64 | +0.11 | +7.2% | $1.53 | $1.80 | $1.53 | 246,600 | |
| $1.53 | +0.07 | +4.8% | $1.44 | $1.53 | $1.44 | 37,900 | |
| $1.46 | +0.02 | +1.4% | $1.45 | $1.495 | $1.45 | 42,100 | |
| $1.44 | -0.03 | -2.0% | $1.47 | $1.47 | $1.43 | 42,200 |
Splits
4 splits since 2019 · NASDAQ:MTVA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-11 | Consolidation | |
| 1-for-8 | Consolidation | |
| 1-for-30 | Consolidation | |
| 1-for-25 | Consolidation |
- Ticker
- NASDAQ:MTVA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
Latest deck · Nov 13, 2026
Corporate Update (November 2026)
Corporate update · 42 slides
Latest news
MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
Nov 17, 2026
Closed $1.25 (+3.7%) on Nov 17, 2026
MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026
Nov 16, 2026
Closed $1.21 (-7.3%) on Nov 16, 2026
MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 13, 2026
Closed $1.30 (0.0%) on Nov 13, 2026
MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial
Nov 12, 2026
Closed $1.30 (-9.7%) on Nov 12, 2026
MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026
Nov 9, 2026
Closed $1.61 (+12.6%) on Nov 9, 2026
MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data
Nov 5, 2026
Closed $1.09 (-18.7%) on Nov 5, 2026
MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
Oct 28, 2026
Closed $1.14 (-0.9%) on Oct 28, 2026
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
Oct 13, 2026
Closed $1.43 (-1.4%) on Oct 13, 2026
MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
Sep 9, 2026
Closed $1.74 (+2.4%) on Sep 9, 2026
MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 6, 2026
Closed $1.49 (+2.8%) on Aug 7, 2026
MetaVia Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 34 in the last 12 months · 116 in all · newest Nov 17, 2026 · oldest 2021
- Decks
- 26 decks · latest Nov 13, 2026
Where MetaVia Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MTVA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:MTVA | BOATS | United States | USD |
Valuation
Price/book 2.8× against a median of 2.7×: 6th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$1.97M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.22
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| MetaVia Inc. · NASDAQ:MTVA | US$6.81M | −US$1.97M | n/a | n/a | n/a | 2.8× | n/a | 0.0× | 1.22 |
| AEON Biopharma, Inc. · AMEX:AEON | US$7.27M | −US$4.15M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.04 |
| Pila Pharma AB · OMXSTO:PILA | US$7.01M | US$6.70M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | n/a |
| Cadrenal Therapeutics, Inc. · NASDAQ:CVKD | US$7.01M | US$3.95M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.60 |
| Ensysce Biosciences, Inc. · NASDAQ:ENSC | US$7.00M | −US$22.51M | n/a | −3.6× | n/a | 0.3× | n/a | 0.0× | 1.28 |
| Arctic Bioscience AS · OSL:ABS | US$7.00M | US$11.38M | n/a | 2.8× | n/a | 0.4× | −102.3% | 0.3× | n/a |
| Alaunos Therapeutics, Inc. · NASDAQ:TCRT | US$6.99M | US$6.37M | n/a | 2,124× | n/a | 7.2× | n/a | 0.0× | 0.90 |
| Curanex Pharmaceuticals Inc · NASDAQ:CURX | US$6.92M | US$5.88M | n/a | n/a | n/a | 2.7× | n/a | 0.2× | 0.84 |
| Cambium Bio Ltd · ASX:CMB | US$6.82M | US$6.18M | n/a | 14.6× | n/a | 4.3× | −638.4% | 0.1× | n/a |
| Aligos Therapeutics, Inc. · NASDAQ:ALGS | US$6.64M | −US$12.55M | n/a | −2.1× | n/a | 0.6× | n/a | 1.1× | 1.63 |
| ZEO ScientifiX Inc. · OTC:ZEOX | US$6.51M | US$5.27M | n/a | 1.0× | n/a | n/a | −106.2% | n/a | 0.54 |
| Median of the others | US$6.99M | US$5.57M | 1.9× | 2.7× | −106.2% | 0.0× | 1.04 |
Forecasts
1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 19.33 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.52 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Hyung Heon Kim | Chief Executive Officer and President |
| Marshall H. Woodworth | Chief Financial Officer |
| Sarah Browne | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Andrew Koven | Chairman of the Board |
| D. Gordon Strickland | Independent Director |
| Hyung Heon Kim | Chief Executive Officer and President |
| James P. Tursi | Independent Director |
| Jason Groves | Independent Director |
| Mark A. Glickman | Independent Director |
| Michael Salsbury | Independent Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · Before open | 0.0% |
| Q2 2026 | Aug 6, 2026 · After close | +2.8% |
| Q1 2026 | May 14, 2026 · After close | −6.7% |
| Q3 2025 | Nov 6, 2025 · Before open | −15.0% |
| Q2 2025 | Aug 7, 2025 · Before open | +2.9% |
| Q1 2025 | May 14, 2025 | +4.0% |
| Q4 2024 | Mar 20, 2025 · Before open | −2.5% |
| Q3 2024 | Nov 7, 2024 · Before open | −2.2% |
| Q2 2024 | Aug 14, 2024 · Before open | +3.2% |
| Q1 2024 | May 9, 2024 | +0.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 28, 2024 · After close | −0.7% |
| Q3 2023 | Nov 13, 2023 · After close | −1.8% |
| Q2 2023 | Aug 9, 2023 · After close | +13.2% |
| Q1 2023 | May 12, 2023 · After close | +3.1% |
| Q4 2022 | Mar 30, 2023 | −2.7% |
| Q3 2022 | Nov 14, 2022 · After close | +10.1% |
| Q2 2022 | Aug 16, 2022 | −2.0% |
| Q1 2022 | May 25, 2022 | −15.2% |
| Q3 2021 | Nov 15, 2021 · Before open | +1.1% |
| Quarter to Jun 30, 2021 | Aug 16, 2021 · Before open | +1.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 42 slides | Nov 13, 2026 |
| Investor Presentation (November 2026) | Investor deck | 54 slides | Nov 5, 2026 |
| Investor Presentation (August 2026) | Investor deck | 37 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 37 slides | May 14, 2026 |
| Investor Presentation (March 2026) | Investor deck | 37 slides | Mar 26, 2026 |
| IPO Roadshow (January 2026) | IPO roadshow | 52 slides | Jan 6, 2026 |
| Investor Presentation (November 2025) | Investor deck | 30 slides | Nov 6, 2025 |
| Investor Presentation (August 2025) | Investor deck | 30 slides | Aug 7, 2025 |
| Investor Presentation (May 2025) | Investor deck | 30 slides | May 21, 2025 |
| Investor Presentation (April 2025) | Investor deck | 29 slides | Apr 22, 2025 |
All 26 decks
Financings
| Raise | Date |
|---|---|
| Public offering of class A Units and Class B Units (common stock or equivalents with Series C and Series D Warrants) Closed: US$9.3M raised · US$3.1 a unit · Warrants at US$3.1 for 60 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: Working capital and general corporate purposes, including continued clinical development of DA-1726 for obesity | Jan 16, 2026 |
| Private placement of common stock and pre-funded warrants Closed: US$10M raised · US$0.71 a share · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: Working capital and corporate purposes, including continued clinical development of DA-1726 for obesity | May 14, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Gemphire Therapeutics Inc. Priced at US$10.00 a share on Aug 4, 2016.
- Price
- US$10.00 a share
- Shares offered
- 3,000,000 shares of common stock
- Offering size
- US$30 million
- Underwriters' option
- Up to 450,000 more shares
- Listing
- GEMP on the Nasdaq Global Market
- Underwriters
- Jefferies, RBC Capital Markets, Canaccord Genuity, Laidlaw & Company (UK) Ltd., LifeSci Capital · In the order on the cover
- Shares delivered
- On or about Aug 10, 2016
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 11, 2015 |
| Filed publicly | Apr 18, 2016 |
| Amended twice | Newest Aug 4, 2016 |
| Shares registered with an exchange | Jun 20, 2016 |
| Declared effective by the SEC | Aug 4, 2016 |
| Final prospectus, with the price | Aug 8, 2016 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 8, 2016 |
| FWP · Free writing prospectus | Aug 5, 2016 |
| EFFECT · Notice that a registration is effective | Aug 4, 2016 |
| CORRESP · Letter to the SEC | Aug 4, 2016 |
| CORRESP · Letter to the SEC | Aug 4, 2016 |
| S-1/A · Registration statement, amended | Aug 4, 2016 |
| CORRESP · Letter to the SEC | Jul 8, 2016 |
| CORRESP · Letter to the SEC | Jul 8, 2016 |
| CERTNAS · Nasdaq's certificate of listing | Jun 21, 2016 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 20, 2016 |
All 23 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 20, 2016 |
| CORRESP · Letter to the SEC | Jun 20, 2016 |
| CORRESP · Letter to the SEC | Jun 15, 2016 |
| S-1/A · Registration statement, amended | Jun 13, 2016 |
| CORRESP · Letter to the SEC | May 3, 2016 |
| UPLOAD · Letter from the SEC | May 2, 2016 |
| CORRESP · Letter to the SEC | Apr 22, 2016 |
| S-1 · Registration statement | Apr 18, 2016 |
| DRSLTR · Letter to the SEC with a draft | Jan 19, 2016 |
| DRS/A · Draft registration statement, amended | Jan 19, 2016 |
| UPLOAD · Letter from the SEC | Oct 7, 2015 |
| DRSLTR · Letter to the SEC with a draft | Sep 11, 2015 |
| DRS · Draft registration statement | Sep 11, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 8, 2016
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Cost of revenue | 19.0K | 24.0K | 7.00K | 28.0K | 72.0K | 67.0K | ||||
| Gross profit | -19.0K | -24.0K | -7.00K | -28.0K | -72.0K | -67.0K | ||||
| Research and development | 6.80M | 21.6M | 9.16M | 2.78M | 6.55M | 4.53M | 5.32M | 5.07M | 22.7M | 8.74M |
| Selling, general and administrative | 6.91M | 7.26M | 6.73M | 8.64M | 8.75M | 7.85M | 2.70M | 1.60M | 10.4M | 5.96M |
| Operating income | -13.7M | -28.8M | -15.9M | -19.6M | -15.3M | -29.7M | -20.2M | -15.5M | -33.1M | -14.7M |
| Depreciation and amortization | 19.0K | 20.0K | 6.00K | 20.0K | 48.0K | 46.0K | 17.0K | |||
| EBITDA | -13.7M | -28.8M | -15.9M | -19.6M | -15.3M | -29.7M | -20.2M | |||
| Interest expense | 0 | 2.19M | 0 | 22.0K | 40.0K | 286.0K | ||||
| Income before tax | -13.0M | -27.6M | -12.5M | -14.0M | -15.3M | -29.7M | -21.3M | -15.5M | -33.4M | -14.6M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -13.0M | -27.6M | -12.5M | -14.0M | -15.3M | -29.7M | -21.3M | -15.5M | -33.4M | -14.6M |
| Earnings per share, basic | -7.35 | -39.13 | -2.46 | -43.42 | -19.81 | -1.83 | -4.08 | -3.65 | -3.23 | -2.57 |
| Earnings per share, diluted | -7.35 | -39.13 | -2.46 | -43.42 | -19.81 | -1.83 | -4.08 | -3.65 | -3.23 | -2.57 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 10.3M | 16.0M | 22.4M | 33.4M | 16.4M | 10.1M | 13.9M | 2.85M | 18.5M | 24.0M |
| Current assets | 10.9M | 16.1M | 22.5M | 33.5M | 16.6M | 10.7M | 14.1M | 3.81M | 19.0M | 24.7M |
| Property, plant and equipment | 17.0K | 34.0K | 46.0K | 2.00K | 110.0K | 155.0K | 200.0K | 3.00K | ||
| Total assets | 11.1M | 16.3M | 22.8M | 33.5M | 16.8M | 11.0M | 14.5M | 3.82M | 19.0M | 24.8M |
| Accounts payable | 1.06M | 3.88M | 821.0K | 708.0K | 830.0K | 2.58M | 638.0K | 170.0K | 4.03M | 2.01M |
| Current liabilities | 5.65M | 8.27M | 5.96M | 11.8M | 2.16M | 3.69M | 2.08M | 219.0K | 6.39M | 4.12M |
| Total debt | 210.0K | 136.0K | 203.0K | 71.0K | 94.0K | 116.0K | 9.58M | 10.0M | ||
| Total liabilities | 5.79M | 8.33M | 6.10M | 11.8M | 2.20M | 3.77M | 2.18M | 360.0K | 15.1M | 4.12M |
| Shareholders' equity | 5.33M | 7.93M | 16.7M | 21.8M | 14.6M | 7.20M | 12.3M | -13.3M | 25.0K | 20.6M |
| Shares outstanding | 2.31M | 785.2K | 4.91M | 3.18M | 888.7K | 19.7M | 15.6M | 5.17M | 10.6M | 9.27M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -15.7M | -24.7M | -10.8M | -11.7M | -15.1M | -10.8M | -7.04M | -14.5M | -26.9M | -11.0M |
| Capital spending | -2.00K | -8.00K | -50.0K | 0 | -3.00K | -4.00K | -214.0K | -3.00K | 0 | 0 |
| Free cash flow | -15.7M | -24.7M | -10.8M | -11.7M | -15.1M | -10.8M | -7.25M | -14.5M | -26.9M | -11.0M |
| Cash from investing | -2.00K | -8.00K | -50.0K | 8.00K | -586.0K | 69.0K | -6.06M | -3.00K | ||
| Cash from financing | 9.96M | 18.3M | -80.0K | 28.7M | 22.0M | 6.86M | 24.2M | 17.2M | 21.3M | 31.5M |
| Change in cash | -5.74M | -6.42M | -10.9M | 17.0M | 6.31M | -3.84M | 11.1M | 481.0K | -5.56M | 20.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 18, 2026 | Current report | SEC |
| 8-K · Current report | Nov 17, 2026 | Current report | SEC |
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 8-K · Current report | Nov 12, 2026 | Current report | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
| 8-K · Current report | Oct 28, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 13, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 8-K · Current report | Jul 9, 2026 | Current report | SEC |
| 8-K · Current report | Jul 2, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jul 2, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 8, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 8, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 8, 2026 | Current report | SEC |
| 8-K · Current report | May 27, 2026 | Current report | SEC |
| 8-K · Current report | May 18, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 8-K · Current report | May 11, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 27, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 15, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 10, 2026 | Current report | SEC |
| 424B3 · Prospectus | Apr 7, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 7, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Apr 3, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Apr 3, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 26, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 8-K · Current report | Mar 18, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 27, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 16, 2026 | Material contract | SEC |
| 424B4 · Prospectus | Jan 16, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 16, 2026 | Other filings | SEC |
| S-1MEF · Registration of more shares for the same offering | Jan 15, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 14, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 14, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 12, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 7, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 7, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 5, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 5, 2026 | Other filings | SEC |
| FWP · Free writing prospectus | Jan 5, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 5, 2026 | Results | SEC |
| S-1 · Registration statement | Jan 5, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 5, 2026 | Current report | SEC |
| 8-K · Current report | Dec 19, 2025 | Current report | SEC |
| 8-K · Current report | Dec 2, 2025 | Current report | SEC |
| 8-K · Current report | Nov 26, 2025 | Current report | SEC |
| 8-K · Current report | Nov 7, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 6, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 6, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| DRS · Draft registration statement | Oct 17, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 7, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 8-K · Current report | Aug 6, 2025 | Current report | SEC |
| 8-K · Current report | Aug 4, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 11, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jul 10, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 9, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Jul 8, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 8, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 2, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2025 | Meeting outcome | SEC |
| ARS · Annual report to shareholders | Jun 9, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 9, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 8-K · Current report | May 30, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | May 27, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 21, 2025 | Current report | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 20, 2025 | Big-stake notice | SEC |
| D | May 15, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 8-K · Current report | May 14, 2025 | Material contract | SEC |
| 8-K · Current report | May 7, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | May 6, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 2, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 28, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 22, 2025 | Current report | SEC |
| 8-K · Current report | Apr 15, 2025 | Current report | SEC |
| 8-K · Current report | Apr 15, 2025 | Current report | SEC |
| 424B3 · Prospectus | Apr 4, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 4, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| 8-K · Current report | Dec 18, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 29, 2024 | Current report | SEC |
| 8-K · Current report | Nov 18, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 8-K · Current report | Nov 4, 2024 | Current report | SEC |
| 8-K · Current report | Oct 7, 2024 | Current report | SEC |
| 8-K · Current report | Sep 30, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 20, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 19, 2024 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Aug 21, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2024 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Aug 7, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 6, 2024 | Current report | SEC |
| 8-K · Current report | Jul 30, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 25, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Jul 24, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 22, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 22, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jul 18, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 16, 2024 | Current report | SEC |
| 4/A · Change in ownership, amended | Jul 10, 2024 | Insider trade | SEC |
| D | Jul 1, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 26, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 25, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Jun 25, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 25, 2024 | Material contract | SEC |
| 8-K · Current report | Jun 24, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2024 | Management or board change | SEC |
| 8-K · Current report | May 22, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 30, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 24, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 19, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 17, 2024 | Other filings | SEC |
| 8-K · Current report | Apr 17, 2024 | Current report | SEC |
| 8-K · Current report | Apr 16, 2024 | Current report | SEC |
| S-3 · Registration statement | Apr 12, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 1, 2024 | Current report | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| 8-K · Current report | Mar 13, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2024 | Management or board change | SEC |
| 8-K · Current report | Feb 29, 2024 | Current report | SEC |
| 8-K · Current report | Feb 14, 2024 | Current report | SEC |
| 8-K · Current report | Feb 1, 2024 | Current report | SEC |
| 8-K · Current report | Jan 18, 2024 | Current report | SEC |
| 8-K · Current report | Jan 9, 2024 | Current report | SEC |
| 8-K · Current report | Dec 28, 2023 | Current report | SEC |
| 8-K · Current report | Dec 19, 2023 | Current report | SEC |
| 8-K · Current report | Dec 7, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 4, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 8-K · Current report | Nov 6, 2023 | Management or board change | SEC |
| 3 · Initial statement of ownership | Nov 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 30, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 30, 2023 | Management or board change | SEC |
| 8-K · Current report | Sep 22, 2023 | Current report | SEC |
| 8-K · Current report | Sep 19, 2023 | Management or board change | SEC |
| 8-K · Current report | Sep 15, 2023 | Current report | SEC |
| 8-K · Current report | Aug 24, 2023 | Material contract | SEC |
This page holds 200 of 639 filings. Open Filings
Cap table
Built by 6ix from MetaVia Inc.’s releases · as of Nov 9, 2026
- Common shares
- 6,742,889
- Fully diluted
- 6,742,889
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 6,742,889 | Nov 9, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$3.10 · expire about Jan 2031 |
Share count over time
| Count | Shares |
|---|---|
| Nov 9, 2026 | 6,742,889 |
| Sep 30, 2026 | 6,742,889 |
| Mar 31, 2026 | 2,308,294 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Mark A. Glickman Other companies: BioStem Technologies, Inc. (Director · Since at least Aug 6, 2026); TherapeuticsMD, Inc. (Co-Chief Executive Officer · Oct 15, 2021 – Dec 6, 2022 · Past); Esperion Therapeutics, Inc. (Chief Commercial Officer · Dec 20, 2018 – Jan 2, 2020 · Past); Aralez Pharmaceuticals Inc (Chief Commercial Officer · Feb 5, 2016 – Mar 19, 2018 · Past); POZEN Inc (Chief Commercial Officer · Jun 22, 2015 – Jun 22, 2015 · Past); Auxilium Pharmaceuticals Inc (EVP - Sales and Marketing · Feb 3, 2012 – Jan 29, 2015 · Past) | Independent Director · Since at least May 11, 2023 |
| Andy Sassine Other companies: Arcturus Therapeutics Holdings Inc. (Chief Financial Officer, Director · Since at least Jan 1, 2019); icad inc (Director · Since at least Dec 7, 2015); Exicure, Inc. (Director · Mar 5, 2021 – Jun 2, 2021 · Past); Acorn Energy, Inc. (Director · Sep 20, 2013 – Sep 23, 2014 · Past); Emmaus Life Sciences, Inc. (Director · Feb 25, 2013 – Apr 5, 2016 · Past) | Director · Aug 4, 2016 – Jul 24, 2019 · Past |
| James P. Tursi Other companies: Endo International PLC (Executive VP, Global R&D · Feb 24, 2022 – Jul 15, 2022 · Past); Antares Pharma Inc (EVP, Chief Medical Officer · Aug 6, 2018 – Jun 13, 2019 · Past); Aralez Pharmaceuticals Inc (Chief Medical Officer · Feb 5, 2016 – May 14, 2018 · Past); POZEN Inc (Chief Medical Officer · Oct 1, 2015 – Oct 1, 2015 · Past); Auxilium Pharmaceuticals Inc (Chief Medical Officer · Feb 14, 2012 – Jan 29, 2015 · Past) | Independent Director · Since at least Nov 1, 2023 |
| Lee Golden Other companies: Cadrenal Therapeutics, Inc. (Board Member · Since at least Nov 24, 2025); PTC Therapeutics, Inc. (EVP & CHIEF MEDICAL OFFICER · Since at least Jun 6, 2023) | Chief Medical Officer · Oct 5, 2016 – Jan 28, 2018 · Past |
| Jason Groves Other companies: Medifast Inc (Executive VP & General Counsel, Director · Apr 6, 2010 – Feb 17, 2015 · Past) | Independent Director · Since at least Dec 30, 2019 |
| Akash Bakshi | SVP and COO, Director · Dec 31, 2020 – Dec 31, 2020 · Past |
| Andrew Koven | Chairman of the Board · Since at least Jun 8, 2026 |
| David Lowenschuss | Chief Legal Off. & Secretary · Aug 4, 2016 – Aug 10, 2016 · Past |
| D. Gordon Strickland | Director · Since at least Jan 27, 2022 |
| Hyung Heon Kim | Chief Executive Officer and President · Since at least Jul 9, 2021 |
All 17 people
| Person | Seat |
|---|---|
| Jeong Gyun Oh | Director · Dec 30, 2019 – Jan 13, 2020 · Past |
| Joseph Hooker | Interim CEO and President · Jan 12, 2023 – Jan 12, 2023 · Past |
| Marshall H. Woodworth | Chief Financial Officer · Since at least Oct 28, 2026 |
| Michael Salsbury | Director · Since at least Jun 9, 2022 |
| Nicola Shannon | VP, Clinical Operations · Dec 30, 2019 – Dec 30, 2019 · Past |
| Richard Kang | Director · Dec 30, 2019 – Jun 9, 2022 · Past |
| Sarah Browne | Chief Medical Officer · Since at least Oct 12, 2026 |
Log in to ask 6ix AI your own questions about MetaVia Inc.